• Mashup Score: 0
    Dr. Scott Solomon: Dapagliflozin Benefits Patients With Heart Failure, Kidney Disease - 8 month(s) ago

    Home > ESC Congress 2023 > Dr. Scott Solomon: Dapagliflozin Benefits Patients With Heart Failure, Kidney Disease A pooled analysis from the DELIVER and DAPA-HF trials assessed the efficacy of FARXIGA (dapagliflozin) in patients with heart failure and deteriorating kidney function. The findings, which demonstrated clinical benefit, were presented at the European Society of Cardiology Congress 2023. In this exclusive interview, DocWire News spoke with the presenting investigator, Dr. Scott Solomon, of

    Source: www.docwirenews.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of mydocwire
      mydocwire

      Dr. Scott Solomon discussed a pooled analysis from the DELIVER and DAPA-HF trials which showed the clinical benefit of #dapagliflozin in patients with #heartfailure and deteriorating kidney function. #kidneydisease #ESCCongress #ESC2023 https://t.co/eh9toWDtwi https://t.co/7ydnh5ggaQ

  • Mashup Score: 0
    FDA expands dapagliflozin indication to include all patients with HF - 12 month(s) ago

    The FDA expanded an indication for the SGLT2 inhibitor dapagliflozin to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction, according to an industry press release.Dapagliflozin (Farxiga, AstraZeneca) was previously approved in the U.S. for adults with HF with reduced EF.

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      ICYMI: The FDA expanded an indication for the SGLT2 inhibitor #dapagliflozin to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction @EndocrineToday @US_FDA #cardiotwitter https://t.co/kW84TX7pNw

  • Mashup Score: 0
    FDA expands dapagliflozin indication to include all patients with HF - 12 month(s) ago

    The FDA expanded an indication for the SGLT2 inhibitor dapagliflozin to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction, according to an industry press release.Dapagliflozin (Farxiga, AstraZeneca) was previously approved in the U.S. for adults with HF with reduced EF.

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      ICYMI: The FDA expanded an indication for the SGLT2 inhibitor #dapagliflozin to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction @EndocrineToday @US_FDA #cardiotwitter https://t.co/kW84TX7pNw

Load More